DentaCore Group, a Swiss dental platform, has secured CHF150 million (US$190 million) in financing to repay existing debt and fund future acquisitions. The package includes a term loan, revolving credit facility and incremental facility. Founded in 2021, DentaCore specialises in acquiring and consolidating dental practices, clinics and laboratories. The company has rapidly scaled to over 60 dental practices and laboratories through more than 40 acquisitions. UBS served as sole mandated lead arranger, bookrunner and agent for a CHF120 million term loan and revolving credit facility. Houlihan Lokey acted as exclusive financing adviser, whilst MLL Legal provided legal counsel. In 2025, Capital Transmission, a Swiss investment company within the BCGE Group, invested in DentaCore.

UBS has increased its stake in Luye Pharma (02186) by 13.95 million shares at approximately HK$2.85 per share, for a total consideration of around HK$39.84 million, according to Hong Kong Stock Exchange filings dated 2 April. Following the transaction, UBS now holds approximately 403 million shares, representing a 10.09% stake in the company. The filing notes that 218.5 million of the reported positions relate to a securities lending agreement executed alongside a convertible bond issuance disclosed on 28 June 2023.

Advestra advised UBS Switzerland as coordinator, agent, fronting bank and lender, alongside the other syndicate banks as lenders, on the CHF 100 million credit facility provided to Gasverbund Mittelland, a procurement and grid company of natural and biogas active across the Plateau and Northwestern regions in Switzerland.